Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EBT (2016 - 2025)

Mimedx (MDXG) has disclosed EBT for 15 consecutive years, with $21.8 million as the latest value for Q4 2025.

  • Quarterly EBT rose 93.75% to $21.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.3 million through Dec 2025, up 15.66% year-over-year, with the annual reading at $66.3 million for FY2025, 15.65% up from the prior year.
  • EBT hit $21.8 million in Q4 2025 for Mimedx, down from $22.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $23.2 million in Q2 2024 to a low of -$10.8 million in Q2 2022.
  • Historically, EBT has averaged $6.1 million across 5 years, with a median of $9.3 million in 2023.
  • Biggest YoY gain for EBT was 10732.97% in 2022; the steepest drop was 505.72% in 2022.
  • Year by year, EBT stood at $91000.0 in 2021, then soared by 10732.97% to $9.9 million in 2022, then soared by 41.13% to $13.9 million in 2023, then decreased by 19.15% to $11.2 million in 2024, then surged by 93.75% to $21.8 million in 2025.
  • Business Quant data shows EBT for MDXG at $21.8 million in Q4 2025, $22.8 million in Q3 2025, and $13.0 million in Q2 2025.